Immunogenic composition
AssigneeGlaxosmithkline Biologicals SA
InventorsRalph Leon Biemans, Dominique Boutriau, Carine Capiau, Philippe Denoel, Pierre Duvivier, Jan Poolman
Life of this patent
Estimating the term…
Abstract
The present application discloses an immunogenic composition comprising at least 2 different N. meningitidis capsular saccharides, wherein one or more is/are selected from a first group consisting of MenA, MenC, MenY and MenW which is/are conjugated to a protein carrier(s) wherein the saccharide:protein ratio (w/w) is between 1:2-1:5, and one or more different saccharides is/are selected from a second group consisting of MenA, MenC, MenY and MenW which is/are conjugated to a protein carrier(s) wherein the saccharide:protein ratio (w/w) is between 5:1-1:1.99.
Claims7
An immunogenic composition comprising
- (a) N. meningitidis serogroup A capsular saccharide conjugated to a linker by 1-cyano-4-dimethylamino pyridinium tetrafluoroborate chemistry, wherein the linker is conjugated to tetanus toxoid carrier protein by carbodiimide chemistry;
- (b) N. meningitidis serogroup C capsular saccharide conjugated to a linker by 1-cyano-4-dimethylamino pyridinium tetrafluoroborate chemistry, wherein the linker is conjugated to tetanus toxoid carrier protein by carbodiimide chemistry;
- (c) N. meningitidis serogroup W capsular saccharide directly conjugated to tetanus toxoid carrier protein by 1-cyano-4-dimethylamino pyridinium tetrafluoroborate chemistry;
- and
- (d) N. meningitides serogroup Y capsular saccharide directly conjugated to tetanus toxoid carrier protein by 1-cyano-4-dimethylamino pyridinium tetrafluoroborate chemistry.
Dependencies are inferred from the claim text.